Screening for bladder cancer using urine-based tumor markers

R. S. Svatek, Yair Lotan, P. I. Karakiewizc, S. F. Shariat

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as hematuria, or a history of bladder cancer. The ultimate goal of cancer screening is to decrease cancer-related mortality by detecting disease prior to the time that the disease would normally prompt evaluation from symptoms. There are several features of urothelial carcinoma of the bladder which make screening for this disease an attractive alternative to the current approach to this disease. The disease targets a defined population and survival for patients with this disease is strongly associated with disease stage at presentation. In addition, quick, easy, and painless screening tests are theoretically possible using tumor-related markers because of the direct exposure of caner cells to urine. Indeed, recent insights into the biology of bladder cancer initiation and progression have resulted in the identification of several urine-based markers which have promise for detecting the presence of bladder cancer. Nevertheless, adoption of screening programs prior to establishing evidence of effectiveness and large-scale financial considerations has substantial damaging consequences. This article reviews the current literature regarding screening for bladder cancer using urine-based markers.

Original languageEnglish (US)
Pages (from-to)247-253
Number of pages7
JournalMinerva Urologica e Nefrologica
Volume60
Issue number4
StatePublished - Dec 2008

Fingerprint

Tumor Biomarkers
Urinary Bladder Neoplasms
Urine
Early Detection of Cancer
Symptom Assessment
Hematuria
Urinary Bladder
Carcinoma
Survival
Mortality
Population
Neoplasms

Keywords

  • Screeening
  • Tumor markers, biological
  • Urinary bladder neoplasms, diagnosis

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Svatek, R. S., Lotan, Y., Karakiewizc, P. I., & Shariat, S. F. (2008). Screening for bladder cancer using urine-based tumor markers. Minerva Urologica e Nefrologica, 60(4), 247-253.

Screening for bladder cancer using urine-based tumor markers. / Svatek, R. S.; Lotan, Yair; Karakiewizc, P. I.; Shariat, S. F.

In: Minerva Urologica e Nefrologica, Vol. 60, No. 4, 12.2008, p. 247-253.

Research output: Contribution to journalArticle

Svatek, RS, Lotan, Y, Karakiewizc, PI & Shariat, SF 2008, 'Screening for bladder cancer using urine-based tumor markers', Minerva Urologica e Nefrologica, vol. 60, no. 4, pp. 247-253.
Svatek, R. S. ; Lotan, Yair ; Karakiewizc, P. I. ; Shariat, S. F. / Screening for bladder cancer using urine-based tumor markers. In: Minerva Urologica e Nefrologica. 2008 ; Vol. 60, No. 4. pp. 247-253.
@article{81cb9a22235242e9a6729e201503382e,
title = "Screening for bladder cancer using urine-based tumor markers",
abstract = "Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as hematuria, or a history of bladder cancer. The ultimate goal of cancer screening is to decrease cancer-related mortality by detecting disease prior to the time that the disease would normally prompt evaluation from symptoms. There are several features of urothelial carcinoma of the bladder which make screening for this disease an attractive alternative to the current approach to this disease. The disease targets a defined population and survival for patients with this disease is strongly associated with disease stage at presentation. In addition, quick, easy, and painless screening tests are theoretically possible using tumor-related markers because of the direct exposure of caner cells to urine. Indeed, recent insights into the biology of bladder cancer initiation and progression have resulted in the identification of several urine-based markers which have promise for detecting the presence of bladder cancer. Nevertheless, adoption of screening programs prior to establishing evidence of effectiveness and large-scale financial considerations has substantial damaging consequences. This article reviews the current literature regarding screening for bladder cancer using urine-based markers.",
keywords = "Screeening, Tumor markers, biological, Urinary bladder neoplasms, diagnosis",
author = "Svatek, {R. S.} and Yair Lotan and Karakiewizc, {P. I.} and Shariat, {S. F.}",
year = "2008",
month = "12",
language = "English (US)",
volume = "60",
pages = "247--253",
journal = "Minerva Urologica e Nefrologica",
issn = "0393-2249",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Screening for bladder cancer using urine-based tumor markers

AU - Svatek, R. S.

AU - Lotan, Yair

AU - Karakiewizc, P. I.

AU - Shariat, S. F.

PY - 2008/12

Y1 - 2008/12

N2 - Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as hematuria, or a history of bladder cancer. The ultimate goal of cancer screening is to decrease cancer-related mortality by detecting disease prior to the time that the disease would normally prompt evaluation from symptoms. There are several features of urothelial carcinoma of the bladder which make screening for this disease an attractive alternative to the current approach to this disease. The disease targets a defined population and survival for patients with this disease is strongly associated with disease stage at presentation. In addition, quick, easy, and painless screening tests are theoretically possible using tumor-related markers because of the direct exposure of caner cells to urine. Indeed, recent insights into the biology of bladder cancer initiation and progression have resulted in the identification of several urine-based markers which have promise for detecting the presence of bladder cancer. Nevertheless, adoption of screening programs prior to establishing evidence of effectiveness and large-scale financial considerations has substantial damaging consequences. This article reviews the current literature regarding screening for bladder cancer using urine-based markers.

AB - Bladder cancer screening differs from routine detection of bladder cancer in patients with symptoms, such as hematuria, or a history of bladder cancer. The ultimate goal of cancer screening is to decrease cancer-related mortality by detecting disease prior to the time that the disease would normally prompt evaluation from symptoms. There are several features of urothelial carcinoma of the bladder which make screening for this disease an attractive alternative to the current approach to this disease. The disease targets a defined population and survival for patients with this disease is strongly associated with disease stage at presentation. In addition, quick, easy, and painless screening tests are theoretically possible using tumor-related markers because of the direct exposure of caner cells to urine. Indeed, recent insights into the biology of bladder cancer initiation and progression have resulted in the identification of several urine-based markers which have promise for detecting the presence of bladder cancer. Nevertheless, adoption of screening programs prior to establishing evidence of effectiveness and large-scale financial considerations has substantial damaging consequences. This article reviews the current literature regarding screening for bladder cancer using urine-based markers.

KW - Screeening

KW - Tumor markers, biological

KW - Urinary bladder neoplasms, diagnosis

UR - http://www.scopus.com/inward/record.url?scp=57649135074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649135074&partnerID=8YFLogxK

M3 - Article

C2 - 18923361

AN - SCOPUS:57649135074

VL - 60

SP - 247

EP - 253

JO - Minerva Urologica e Nefrologica

JF - Minerva Urologica e Nefrologica

SN - 0393-2249

IS - 4

ER -